Safety signals with Nintedanib: Case series exploring the adverse effects of Nintedanib in interstitial lung disease

Nintedanib, a Tyrosine Kinase Inhibitor (TKI) with antifibrotic properties, has been approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype and systemic sclerosis- associated ILD (SSc -ILD). Gastrointestinal (GI) adverse effects and Transaminitis were reported commonly with its use. This case series narrates the clinical experiences of patients treated with Nintedanib and highlights the role of Nintedanib in ILD management while emphasizing the need for careful monitoring to optimize safety and treatment outcomes.